

REGD. OFFICE & FACTORY:

Plot No. 161/1, 162, G.I.D.C.,Nandesari-391 340. Dist. Baroda (Gujarat) (İNDIA) Tal. (91) (0265)3065000

Telefax : (91) (0265) 2841351 E-mail : linkpharmachem@hotmail.com

Date: 30.05.2019

To,
Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524748

Dear Sir/Madam,

Sub: Audited Financial Result for the Quarter and Year ended on March 31, 2019.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith:

- 01. Audited Financial Results for the quarter and year ended on March 31, 2019.
- 02. Auditor's Report on Audited Financial Results of the Company for the quarter and year ended March 31, 2019
- 03. A declaration pursuant to Regulation 33 (3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with respect to Auditor's Report with unmodified opinion to the aforesaid Audited Financial Results.

The meeting of the Board of Directors commenced at 02:00 p.m. and concluded at 05:00 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully, For Link Pharma Chem Limited

Bhushan Joshi Company Secretary

Encl: As above



ADMN. OFFICE: 504, Centre Point, R.C. Dutt Road, Alkapuri, Baroda - 390 005. Phone No. 2357595

E-mail: linkpharmalimited@gmail.com CIN: L242300031984P1C 607540

LINK PHARMA CHEM LTD.

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2019

Particulars	Quarter ended			(in Rs. Lakh	
	31.3.2019	31.12.2018	31.3.2018	31.3.2019	31.3.2018
	(Audited)	(unaudited)	(Audited)	(Audited)	(Audited)
Revenue from operations	474.10	607.98	521.36	2,450.01	2,396.4
Other income	11.24	6.13	6.91	19.29	
Total Income (A)	485.34	614.12	528.27	2,469.29	2,403.3
Expenses:			×		
Cost of materials consumed	44.57	436.31	192.73	1,187.48	782.9
Changes in inventories of finished goods and work-in-progress	34.26	(151.37)	16.18	-54.77	206.73
Excise Duty on sales of goods		2 2	1.71	54.77	
Employee benefits expense	239.19	79.88	256.27	471.87	43.23
inance costs	12.18	8.38	26.09		489.78
Depreciation and amortization expense	24.91	21.55	23.78	38.55	61.56
Other Expenses	189.68	152.89	4.56	89.49	85,95
Total expenses (B)	544.78	547.64	521.32	643.67 2,376.29	596.17 2,266.34
Profit before tax (C) = (A-B)	(59.44)	66.48	6.95	93.01	137.05
ax expense:			-		
1) Current tax	(13.90)	14.50	2		
2) MAT credit recognised	(16.46)	14.56	3.16	18.80	27.56
B) Deferred tax			(39.53)	-16.46	(39.53)
otal tax expense (D)	24.85	-	35.54	24.85	35.54
	(5.50)	14.56	(0.83)	27.19	23.57
rofit for the year (E) = (C-D)	(53.94)	51.92	7.78	65.81	113.48
ther Comprehensive Income					
ems that will not be reclassified to profit or loss					
Income tax effect on above	(15.31)	2.12	7.14	-8.94	7.14
miconie tax effect on above	3.56	(0.41)	(1.95)	2.33	(1.95)
	(11.75)	1.71	5.19	-6.60	5.19
tal comprehensive income for the year (Net of Tax)		1444			
	(65.69)	53.64	12.97	59.21	118.67
rnings per equity share (FV of Rs. 10) (Rs.) sic and Diluted	(1.33)	1.21	0.18	1.48	2.56



ADMN. OFFICE:

504, Centre Point, R.C. Dutt Road, Alkapuri, Baroda - 390 005.

Phone No. 2357595

E-mail: linkpharmalimited@gmail.com CIN: 124230GJ1984PLC007540

NOTES:

1 These Financial Results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on 30th May,

2 The Company's operation fall under single segment namely "Chemicals" for the purpose of Indian Accounting standard (Ind As 108) on Segment

3 Consequent to implementation of the Goods and Service Tax (GST) with effect from July 1, 2017, presentation of revenue for the quarters after that date excludes GST and not comparable with prior periods which includes Excise Duty.

4 This statement is as per regulation 33 of the SEBI (listing Obligations and Disclosure Requirement) Regulations, 2015

5 The Company's operation fall under single segment namely "Chemicals" for the purpose of Indian Accounting standard (Ind As 108) on Segment Reporting.

6 The Company confirms that its Statutory Auditors. M/s Sanjay Soni & Associates, have issued unmodified opinion on the financial results.

PLACE: Vadodara DATE: 30.05.2019



RMA

For and behalf of the Board of Link Pharma Chem, Ltd.

> S. G. Thakur Managing Director





Pharma Chem Ud.

AN ISO - 9001 Company

LINK PHARMA CHEM LTD. BALANCE SHEET AS AT 31ST MARCH, 2019

Particulars		(in Rs. Lak		
	As at Ma	rch As at Ma		
	31, 2019	31, 2018		
I. ASSETS				
1. NON CURRENT ASSETS				
(a) Property, Plant and Equipment				
(b) Capital work in progress	913.	72 976.		
(c) Financial Assets	42.	91 1.		
i) Investments	0.0			
ii) Other financial assets	3.0	03 2.5		
(d) Income tax assets (Net)	26.0			
(e) Other non-current assets	72.6			
Total non-current assets	23.6			
	1,081.9	6 1,060.8		
2. CURRENT ASSETS				
(a) Inventories				
(b) Financial Assets	286.92	263,38		
(i) Trade receivables	0.00			
(ii) Cash and cash equivalents	304.32	318.47		
(iii) Bank Ralancos eth	2.47	7,86		
(iii) Bank Balances other than (ii) above (iv) Loans	17.32	10.32		
(v) Other financial assets	9.93	1.93		
(c) Other current assets	2.38	3.25		
Total current assets	95.00	53.05		
	718.33	658.26		
II FOLITY AND Total Assets	1,800.29	1740.44		
II. EQUITY AND LIABILITIES Equity	-,000.23	1,719.16		
	-			
(a) Equity Share capital	444.06			
(b) Other equity		444.06		
Total Equity	594.10 1,038.16	534.89		
164.60	1,038.16	978.95		
Liablities				
Non-current liabilities	- 1	1		
(a) Borrowings	170.0			
(b) Provisions	170.61	224.85		
(c) Deferred tax liabilities (Net)	3.65	3.80		
Total non-current liabilities	100.17	75.31		
Comment to the comment of the commen	274.44	303.97		
Current liabilities				
(a) Financial liabilities				
(i) Borrowings	CE 75			
(ii) Trade payables	65.75	18.62		
(ii) Other financial liabilities	337.14	337.06		
(c) Other current liabilities	55.56	55.04		
otal current liabilities	29.24	25.52		
	487.69	436.24		
Total Equity and liabilities		100.24		

For and on behalf of the Board of Directors of Link Pharma Chem Limited (CIN: L24230GJ1984PLC007540)

5. G. Thakur Managing Director DIN: 00292129



Place: Vadodara DATE: 30.05.2019



ADMN. OFFICE:

504, Centre Point, R.C. Dutt Road, Alkapuri, Baroda - 390 005.

Phone No. 2357595

E-mail: linkpharmalimited@gmail.com CIN: 124230 & J1984 PL c 007540 S -16 C, India Bulls Mega Mall, Dinesh Mill Road, Near Jetalpur Flyover, Akota, Vadodara - 390 007.
(0): 0265-2983872, (M): 98254 83162, E-mail: sanjayesoni@gmail.com

Independent Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015

To
The Board of Directors of Link Pharma Chem Ltd

- We have audited the quarterly financial results of Link Pharma Chem Ltd for the year to date results for the year ended 31st March, 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement which is the responsibility of the company's management which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement.
- We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal financial controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a bsisi for our opinion.

- 3. In our opinion and to the best of our information and according to the explanations given to us , the statement :
 - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - (ii) give a true and fair view in conformity with the aforesaid Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India of the profit (financial performance including other comprehensive income) and other financial information for the quarter ended 31st March, 2019

The statement includes the results for the quarter ended 31st March 2019 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to the limited review by us.

For Sanjay Soni & Associates

Chartered Accountants


FRN 113251W

CA Sanjay Soni

Partner

M No 40616

Date: 30.05.2019 Place: Vadodara



REGD. OFFICE & FACTORY:

Plot No. 161/1, 162, G.I.D.C., Nandesari-391 340. Dist. Baroda (Gujarat) (ÍNDIA) Tal. (91) (0265)3065000 Telefax: (91) (0265) 2841351

E-mail: linkpharmachem@hotmail.com

DECLARATION

Declaration on Audit Report with unmodified opinion pursuant to Regulation 33 (3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We hereby declare that M/s. Sanjay Soni & Associates, Chartered Accountants, (FRN: 113251W) Statutory Auditor of the Company have issued an Audit Report with unmodified opinion and contains no qualification or adverse remark on the Standalone Audited Financial Results for the quarter and year ended on March 31, 2019.

The above declaration is made in compliance with the Regulation 33 (3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For Link Pharma Chem Limited

Satish G Thakur Managing Director

Date: 30.05.2019 Place: Vaddoara

Website: www.linkpharmachem.co.in CIN: L24230GJ1984PLC007540